Research programme: phosphatidylinositol 3-kinase inhibitors - Karus TherapeuticsAlternative Names: KAR-4000; KAR1139; KAR1141; Lipid kinase signaling inhibitors - Karus; PI3K-p110 beta; PI3K-p110 delta
Latest Information Update: 20 Dec 2012
At a glance
- Originator Karus Therapeutics
- Developer Karus Therapeutics; University of London
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation